Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 1/20 | 0.54 |
| ▸ | BMP1 | P13497 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 13/20 | 0.47 |
| ▸ | MMP3 | P08254 | 9/20 | 0.47 |
| ▸ | MMP1 | P03956 | 8/20 | 0.47 |
| ▸ | MMP7 | P09237 | 6/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7118239 | 0.91 | BIRC2 (0.62) | BIRC2BMP1MMP2MMP3MMP1 | |
| SCHEMBL7118243 | 0.91 | BIRC2 (0.62) | BIRC2BMP1MMP2MMP3MMP1 | |
| SCHEMBL7084246 | 0.90 | BIRC2 (0.53) | BIRC2BMP1MMP2MMP3MMP1 | |
| SCHEMBL7118008 | 0.90 | BIRC2 (0.53) | BIRC2BMP1MMP2MMP3MMP1 | |
| SCHEMBL7114508 | 0.89 | BIRC2 (0.52) | BIRC2BMP1MMP2MMP3MMP1 | |
| SCHEMBL7114506 | 0.89 | BIRC2 (0.52) | BIRC2BMP1MMP2MMP3MMP1 | |
| SCHEMBL7077150 | 0.88 | BIRC2 (0.52) | BIRC2BMP1MMP2MMP3MMP1 | |
| SCHEMBL7077148 | 0.88 | BIRC2 (0.52) | BIRC2BMP1MMP2MMP3MMP1 | |
| SCHEMBL7787562 | 0.88 | MME (0.55) | BIRC2BMP1MMP2MMP3MMP1 | |
| SCHEMBL7787564 | 0.88 | MME (0.55) | BIRC2BMP1MMP2MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6476067-B1 | N-formyl hydroxylamine derivatives as antibacterial agents | BRITISH BIOTECH (GB) | 2002-11-05 | — | — | US | claimed |
| EP-1140058-B1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARM (GB) | 2003-11-05 | — | — | EP | disclosed |
| US-20030149084-A1 | Cytostatic agents | AYSCOUGH ANDREW PAUL (GB) | 2003-08-07 | — | — | US | disclosed |
| US-6495597-B1 | N-FORMYL HYDROXYLAMINE DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2002-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149084-A1 | Cytostatic agents | MCTS1, NNMT, MMP12 | BIRC2 930/4885BMP1 3365/4885MMP2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.